# | Filing Date | Period End Date | Type | Report Link |
---|---|---|---|---|
No Data found |
# | Date | Analyst Firm | Upside/Downside | Price Target Change | Rating Change | Current Rating |
---|
Altamira Therapeutics shares are trading higher Thursday after the company announced highlights from its NASAR clinical trial w...
Detailed results from randomized controlled Bentrio® trial in seasonal allergic rhinitis published in Allergy journalStudy met ...
Altamira Therapeutics (NASDAQ:CYTO) reported quarterly losses of $(16.47) per share. This is a 97.38 percent increase over loss...